Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference Transcript
Thank you all for coming. I am Seth Lederman, the CEO of Tonix Pharmaceuticals, and we're on NASDAQ. So, this is our standard Safe Harbor statement. I will be making forward-looking statements. Tonix is a NASDAQ company. We recently did a financing last week. We just closed on a financing, it's a very exciting time for our company. Our lead program is a treatment for Fibromyalgia. That's in Phase-3 development and it's a very big year for us in this program. The Phase-3 program will have an interim analysis in the third quarter of this year, and we expect top line data in the first half of 2021.
So, I'm going to spend most of the time talking about our lead program in fibromyalgia, but I also want to take you through our pipeline. This is the three main programs that we have in central nervous system development. And the first one TNX-102 SL, we are pursuing for three different indications, fibromyalgia, which is in Phase-3 that I mentioned, bedtime treatment for agitation in Alzheimer's, which we have in IND, but have not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
